Fabhalta Capsules specified drug-use survey (C3 glomerulopathy)

Fabhalta Capsules specified drug-use survey (C3 glomerulopathy, CLNP023B11401)

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT2031250387

Enrollment

Registered

2025-09-25

Start date

2025-07-31

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C3 glomerulopathy

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All patients who have used Fabhalta for C3 glomerulopathy (including patients with recurrent C3 glomerulopathy post renal transplant).

Exclusion criteria

Exclusion criteria: Use of iptacopan for an indication not yet approved under the Clinical Trials Act or GCP (e.g., patient-requested medical treatment, investigator-initiated clinical trial)

Design outcomes

Primary

Measure	Time frame
Type, incidence, seriousness, severity, clinical course, presence/absence of factors influencing the onset (status of vaccination, brand name of vaccine administered, status of use of immunosuppressants, name of immunosuppressants used, and complications), and causative bacteria (including serotypes) of infections as adverse events/adverse reactions during the treatment period	—

Contacts

Public ContactNovartis Direct

Novartis Pharma. K.K.

sm.pms@novartis.com+81-120-003-293

Outcome results